@article{d66cd3656b3f43ada490f0b13f0c7b39,
title = "Rapamycin and Alzheimer's disease: Time for a clinical trial?",
abstract = "The drug rapamycin has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer's disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer's disease. We argue that such clinical trials should be undertaken.",
author = "Matt Kaeberlein and Veronica Galvan",
note = "Funding Information: M.K. and V.G. are supported by the University of Washington and UT Health San Antonio Nathan Shock Centers of Excellence in the Basic Biology of Aging, as well as NIH grants P30AG013280 and P30AG013319. Publisher Copyright: Copyright {\textcopyright} 2019 The Authors, some rights reserved;.",
year = "2019",
month = jan,
day = "23",
doi = "10.1126/scitranslmed.aar4289",
language = "English (US)",
volume = "11",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "476",
}